Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma

Summary

This is a multi-centre phase I/II trial with an initial dose finding phase for cyclophosphamide and lenalidomide combined with fixed dose pembrolizumab for patients with relapsed or relapsed / refractory multiple myeloma (MM) that have had at least 1 prior line of therapy

Timeline

Start

2017-08-01

Primary completion

2017-08-01

Completion

2017-08-01

Outcome

Outcome not reported

Stopped (Enrollment): “Withdrawal of pharma support prior to opening to recruitment”

Drugs

Indications